sirna targeting kras proto oncogene gtpase kras (Santa Cruz Biotechnology)
Structured Review

Sirna Targeting Kras Proto Oncogene Gtpase Kras, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+PCR+Microarray/K-Ras+siRNA/pmc05873870-90-14-34
Average 93 stars, based on 30 article reviews
Images
1) Product Images from "Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells"
Article Title: Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells
Journal: International Journal of Oncology
doi: 10.3892/ijo.2018.4324
Figure Legend Snippet: BRD4 knockdown attenuates the proliferation and promotes the apoptosis of U251 cells. (A) A Cell counting kit-8 assay was performed to detect the proliferation of U251 cells transduced with BRD4-shRNA or Scr-shRNA. Each experiment was performed in triplicate. (B) An EdU assay was performed to determine cell proliferation rates following BRD4 knockdown. Nuclei were counterstained blue with DAPI. Red indicates the cells undergoing proliferation. Scale bar, 20 µ m. (C) Quantification of the EdU assay results demonstrated that U251 cell proliferation was reduced following BRD4 knockdown. (D) Representative plots and quantification of flow cytometry analysis of apoptosis following BRD4 knockdown in U251 cells. Data are presented as the mean ± standard deviation of three independent experiments. ** P<0.01. BRD4, bromodomain containing 4; sh, short hairpin; Scr, scrambled control; OD, optical density.
Techniques Used: Knockdown, Cell Counting, Transduction, shRNA, EdU Assay, Flow Cytometry, Standard Deviation, Control
Figure Legend Snippet: Ten key genes identified by global signal transduction network analysis.
Techniques Used: Transduction
Figure Legend Snippet: Experimental validation of microarray results. (A) Reverse transcription-quantitative polymerase chain reaction results for the mRNA expression levels of the ten key genes identified by global signal transduction network analysis. (B) Western blotting validation of the protein expression changes of key genes in the BRD4-shRNA and the Scr-shRNA groups. GAPDH was used as an internal control. (C) Representative photographs and quantification of KRAS immunostaining in normal brain tissue and glioma tissues of grades II, III and IV. Scale bar, 20 µ m. (D) Western blot analysis of KRAS levels in HA and U251 cells. (E) KRAS silencing following siRNA transfection in U251 cells was confirmed by western blotting (at 72 h post-transfection). (F) A cell counting kit-8 assay was performed to detect the proliferation rates of siKRAS and or siCon-transfected U251 cells. Each experiment was performed in triplicate. (G) The apoptosis rates of siKRAS and siCon-transfected U251 cells were determined by TUNEL staining (red). Nuclei were counterstained with DAPI (blue). Scar bar, 50 µ m. Experimental data are presented as the mean ± standard deviation of at least three experiments. * P<0.05 and ** P<0.01. BRD4, bromodomain containing 4; sh, short hairpin; Scr, scrambled control; KRAS, KRAS proto-oncogene GTPase; HA, human astrocytes; si, small interfering; Con, control; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; OD, optical density.
Techniques Used: Biomarker Discovery, Microarray, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Transduction, Western Blot, shRNA, Control, Immunostaining, Transfection, Cell Counting, TUNEL Assay, Staining, Standard Deviation
Related Articles
shRNA:Article Title: High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS. Article Snippet: Background Anoctamin-1 (ANO1) was identified as an unfavorable prognostic marker in pancreatic cancer.. However, the exact implication of ANO1 in pancreatic cancer is still poorly understood.. Here we investigated the effect of ANO1 in pancreatic cancer progression under the context of oncogenic KRAS, aiming at finding a new therapeutic target. Control:Article Title: Inhibiting Isoprenylation Suppresses FcεRI-Mediated Mast Cell Function and Allergic Inflammation. Article Snippet: OVA-HSA was obtained from Sigma-Aldrich. .. Alternaria alternata was obtained from Greer Laboratories (Lenoir, NC). siRNAs for N-Ras (sc-36005), Negative Control:Article Title: Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line. Article Snippet: .. Transfection:Article Title: Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line. Article Snippet: .. |
